Novavax, Inc. (NASDAQ:NVAX) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET
Company Participants
Erika Schultz - Senior Director of IR
John Jacob - President and CEO
John Trizzino - EVP and Chief Commercial Officer
Filip Dubovsky - Chief Medical Officer
James Kelly - EVP and CFO
Rick Crowley - COO
Conference Call Participants
Roger Song - Jefferies
Alec Stranahan - Bank of America Merrill Lynch
Georgi Yordanov - Cowen and Company
Eric Joseph - JPMorgan
Mayank Mamtani - B. Riley Securities FBR
Operator
Ladies and gentlemen, thank you for standing by. And welcome to the Novavax Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] After the speaker’s presentation, there will be a question-and-answer session [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to turn the conference over to your speakers today Erika Schultz. You may begin Maam.
Erika Schultz
Good afternoon, and thank you all for joining us today to discuss our fourth quarter and full year 2022 operational highlights and financial results. A press release announcing our results is currently available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today.
Please turn to Slid two. Before we begin with prepared remarks, I need to remind you that this presentation includes forward-looking statements, including information relating to the future of Novavax, its key strategic priorities, operating plans, objective and prospects.
Its future financial or business performance, conditions or strategies, key commercial goals, future product demand trends, the ongoing development of our vaccine candidates, including strain selection, anticipating timing of trials and results, the scope, timing and outcome of future regulatory filings and actions, the efficacy, safety and intended utilization of our vaccine candidates, including against COVID-19 variants, the global market opportunities for our vaccine candidates, our manufacturing capacity, and the future availability of our vaccine candidates and key upcoming milestones.
Each forward looking statement contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements. Additional information regarding those factors appears under the heading cautionary note regarding forward looking statements in the slide deck we issued this afternoon, and under the heading risk factors, and our most recent form 10-K and subsequent form 10-Q filed with the Securities and Exchange Commission and available@www.sec.gov and on our website at www.novavax.com.